Fibrin D-dimer, Markers of Coagulation Activation and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study

Gordon D. O. Lowe; Ann Rumley; Peter M. Sweetnam; John W. G. Yarnell; Joseph Rumley

doi:10.1055/s-0037-1616138

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 86(03): 822-827
DOI: 10.1055/s-0037-1616138

Review Articles

Schattauer GmbH

Fibrin D-dimer, Markers of Coagulation Activation and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study

Gordon D. O. Lowe

¹University Department of Medicine, Royal Infirmary, Glasgow

,

Ann Rumley

¹University Department of Medicine, Royal Infirmary, Glasgow

,

Peter M. Sweetnam

²MRC Epidemiology Unit (South Wales), Llandough Hospital, Penarth

,

John W. G. Yarnell

³Division of Epidemiology, Queen’s University, Belfast, UK

,

Joseph Rumley

¹University Department of Medicine, Royal Infirmary, Glasgow

› Institutsangaben

Abstract

Summary

We have previously reported that plasma fibrin D-dimer (a marker of turnover of cross-linked fibrin) showed a strong and independent association with incident ischaemic heart disease (IHD) in the Caerphilly Study cohort of 1,998 men aged 49-65. To establish the specificity of this finding, we assayed plasma samples from this cohort with a more specific assay for fibrin D-dimer: this showed an association with incident IHD which was at least as strong and independent as that for the original assay (odds ratio, OR for top fifth compared to bottom fifth 3.79; 95% CI 1.77-8.10; p < 0.0001). To establish potential causes of the increased fibrin turnover, we also assayed several potential markers of coagulation activation or thrombotic tendency (prothrombin fragment F1+2, thrombin-antithrombin complexes, factor VIIc, activated partial thromboplastin time [APTT] and activated protein C resistance): none of these variables were associated with incident IHD in this cohort. We suggest that further studies are required to establish the causes of increased cross-linked fibrin turnover, which is associated with incident IHD in the general population when measured by a specific assay.

Keywords

Fibrin D-dimer - activation markers - ischaemic heart disease

Volltext

Referenzen

References
1 Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of cross-linked fibrin. Biochem Biophys Acta 1973; 295: 308-13.
2 Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis?. Clin Sci 1995; 89: 205-14.
3 Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79: 129-33.
4 Lowe GDO, Rumley A. Use of fibrinogen and fibrin in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667-72.
5 Al-Zahrani H, Lowe GDO, Douglas JT, Cuschieri R, Pollock JG, Smith WCS. Increased fibrin turnover in peripheral arterial disease: comparison with a population study. Clin Hemorheol 1992; 12: 867-72.
6 Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995; 74: 828-32.
7 Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73: 527-33.
8 Lip GYH, Zafiris J, Watson RDS, Bareford D, Lowe GDO, Beevers DG. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-31.
9 Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: analysis of standardization issues and target antigens in plasma. Br J Haematol 1995; 90: 187-94.
10 Hart R, Bate I, Dinh D, Elms M, Bundesen P, Hillyard C, Rylatt DB. The detection of D-dimer in plasma by enzyme immunoassay: improved discrimination is obtained with a more specific signal antibody. Blood Coagul Fibrinolys 1994; 5: 227-32.
11 Mannucci PM. Mechanisms, markers and management of coagulation activation. Br Med Bull 1994; 50: 857-70.
12 Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-71.
13 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-7.
14 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci 1993; 90: 1004-8.
15 Lowe GDO, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV: R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81: 918-24.
16 Sweetnam PM, Yarnell JWG, Lowe GDO, Baker IA, O’Brien JR, Rumley A, Etherington MD, Whitehead PJ, Elwood PC. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol 1998; 100: 582-8.
17 Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study. Br J Haematol 1999; 105: 110-6.
18 Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H. et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-22.
19 Marder VJ, Zareba W, Horan JT, Moss AJ, Kanouse JJ. Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. Thromb Haemost 1999; 82: 1412-6.
20 Yarnell JWG, Sweetnam PM, Rumley A, Lowe GDO. Lifestyle and hemostatic risk factors for ischaemic heart disease. The Caerphilly Study. Arterioscler Thromb Vasc Biol 2000; 20: 271-79.
21 Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol, 1997; 97: 775-84.
22 Lowe GDO, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AGG, Mannucci PM. on behalf of the ECAT, DVT Study Group. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. Thromb Haemost 1999; 81: 879-86.
23 van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong TVM, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-9.
24 Eritsland J, Seljeflot I, Arnesen H, Smith P, Westvik AB. Effects of long-term treatment with warfarin on fibrinogen, FpA, TAT, and D-dimer in patients with coronary artery disease. Thromb Res 1992; 66: 55-60.
25 Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
26 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
27 Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Haemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
28 Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J. et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
29 Kalaria VG, Zareba W, Moss AJ, Pancio G, Marder VJ, Morrissey JH, Weiss HJ, Sparks CE, Greenberg H, Dwyer E, Goldstein R, Watelet LFM. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. Am J Cardiol 2000; 85: 1401-8.
30 Lip GYH, Rumley A, Dunn FG, Lowe GDO. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51: 245-51.
31 Lowe GDO, Yarnell JWG, Rumley A, Bainton D, Sweetnam PM. C-Reactive protein, fibrin D-dimer and incident ischaemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-10.